Study gives first PK data for ertugliflozin in horses: full analysis
Version 2
A newly published study in Veterinary Sciences offers the first formal pharmacokinetic profile of enteral ertugliflozin in horses, giving clinicians long-missing data on a drug that's already found a place in equine metabolic practice. The study evaluated a single oral dose of 0.25 mg/kg in eight healthy horses and found that ertugliflozin was absorbed quickly, reaching peak blood levels in just under an hour on average, with an elimination half-life of roughly 17.7 hours. Those results suggest exposure consistent with once-daily administration, although the authors emphasized that the dose was supratherapeutic relative to common field use. (mdpi.com)
That gap between practice and evidence is what makes the paper notable. Ertugliflozin, an SGLT2 inhibitor developed for human diabetes, has been used by equine clinicians to lower glucose reabsorption and reduce insulin concentrations in horses with insulin dysregulation and hyperinsulinaemia-associated laminitis. But until now, published equine data have centered more on clinical response than on basic pharmacokinetics. A 2022 case series in 51 horses, later highlighted in equine media coverage, helped drive interest by reporting reduced insulin concentrations and improved comfort in laminitic horses treated with oral ertugliflozin, even though the dose in practice was not based on equine PK data. (colab.ws)
The new paper begins to address that. According to the journal summary, non-compartmental analysis found a mean Tmax of 0.91 ± 0.13 hours, Cmax of 267.52 ± 25.37 ng/mL, terminal half-life of 17.65 ± 3.15 hours, and apparent oral clearance of 106.95 ± 27.53 mL/h/kg after enteral administration. The study involved healthy horses rather than horses with insulin dysregulation, and used a single supratherapeutic dose, so the findings don't directly establish the best regimen for clinical patients. Still, they provide a reference point for exposure and duration that veterinarians haven't previously had. (mdpi.com)
Broader equine literature suggests why that matters. Hyperinsulinaemia is a major driver of endocrinopathic laminitis, and SGLT2 inhibitors have drawn attention because they can reduce circulating insulin by promoting urinary glucose loss. A 2025 retrospective case series in Domestic Animal Endocrinology found that horses treated with either ertugliflozin or dapagliflozin had significant reductions in basal insulin by day 30, but also showed increases in triglycerides, cholesterol, beta-hydroxybutyrate, and GGT, with occasional marked hypertriglyceridaemia. The authors concluded that the drugs had similar biochemical effects and that lipid monitoring matters. (sciencedirect.com)
Industry and expert commentary around SGLT2 use in horses has generally been cautiously optimistic rather than unequivocal. Coverage in The Horse has described ertugliflozin as a useful option for difficult hyperinsulinaemia and laminitis cases, while also stressing the need to monitor horses closely and stop treatment if a horse goes off feed or must be fasted. A broader review on SGLT2 inhibitor use in ponies and horses likewise noted that the dose being used in practice has lacked an evidential basis in the horse and called for more work on adverse effects, especially treatment-associated hypertriglyceridaemia. (thehorse.com)
Why it matters: For veterinary professionals, this is less about a practice-changing breakthrough than about strengthening the scientific footing under an already adopted therapy. Equine clinicians managing insulin dysregulation, equine metabolic syndrome, or hyperinsulinaemia-associated laminitis have had to make decisions with limited pharmacologic data. This study doesn't settle efficacy, ideal dose, or long-term safety, but it does support the plausibility of once-daily dosing and gives a clearer starting point for interpreting treatment schedules, blood sampling windows, and future dose-ranging work. It also reinforces that pharmacokinetics and clinical safety need to be considered together, especially in horses at risk for altered lipid metabolism. (mdpi.com)
What to watch: The next important developments will be controlled studies in insulin-dysregulated or laminitic horses, comparisons between currently used field doses and measured drug exposure, and clearer guidance on monitoring triglycerides and feeding status during treatment. If those data emerge, ertugliflozin could move from an experience-driven option toward a more standardized part of endocrine and laminitis management in equine practice. (mdpi.com)